Free shipping on all orders over $ 500

Ladiratuzumab vedotin

Cat. No. M24756
Ladiratuzumab vedotin Structure
Synonym:

SGN-LIV1A

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?
Quality Control & Documentation
Biological Activity

Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC50: 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer.

Chemical Information
CAS Number 1629760-29-7
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Rita De Sanctis, et al. Front Pharmacol. From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds

[2] Ana Isabel Fraguas-Sánchez, et al. Cancers (Basel). Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic

[3] Alessandro Rizzo, et al. Expert Opin Investig Drugs. Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential

[4] Julia E McGuinness, et al. Expert Opin Biol Ther. Antibody-drυg conjugates in metastatic triple negative breast cancer: a spotlight on sacituzumab govitecan, ladiratuzumab vedotin, and trastuzumab deruxtecan

Related Drug-Linker Conjugates for ADC Products
SC-VC-PAB-MMAE

SC-VC-PAB-MMAE is part of a drug-linker conjugate for ADC (ADC) with anticancer activity, which consists of MMAE (a tubulin inhibitor) linked to a cleavable SC-VC-PAB linker.
DBCO-(PEG)3-VC-PAB-MMAE

DBCO-(PEG)3-vc-PAB-MMAE is an active molecule coupler (drug-linker conjugate for ADC) consisting of auristatin E attached to a DBCO-(PEG)3-vc-PAB connector. It can be used for cancer research. In addition, DBCO-(PEG)3-vc-PAB-MMAE is a click chemistry that contains a DBCO moiety and can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing an Azide moiety.
PB038

PB038 is a drug-liker containing a PEG unit and a cleavable linker attached to Exatecan.
Val-Ala-PAB-MMAE

Val-Ala-PAB-MMAE is a Drug-Linker Conjugate for ADC, consisting of ADC linker (Val-Ala-PAB) and MMAE.
Val-Ala-PABC-Exatecan

Val-Ala-PABC-Exatecan is a Drug-Linker Conjugates for ADC, consiting of a cleavable Tesirine linker (Val-Ala-PABC) and Exatecan (topoisomerase I inhibitor).
  Catalog
Abmole Inhibitor Catalog




Keywords: Ladiratuzumab vedotin, SGN-LIV1A supplier, Drug-Linker Conjugates for ADC, inhibitors, activators

 
Get to Know Us
Customer Support
Resources
Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.